Shuttle Pharmaceuticals Holdings, Inc. · NASDAQ:SHPH

Shuttle Pharmaceuticals — Investor Presentation (April 2025)

16 slides from Shuttle Pharmaceuticals's investor presentation, April 2025

1. Slide 1: Investor Presentation Spring 2025

   Shuttle Pharmaceuticals Holdings, Inc. Shuttle Pharmaceuticals, Inc. Shuttle Diagnostics, Inc. Nasdaq: SHPH Investor Presentation Spring 2025

2. Slide 2: Forward Looking Statements

   Forward Looking Statements All of the information contained within this business presentation (the “Presentation”) has been obtained from sources generally believed to be reliable by Shuttle Pharmaceuticals Holdings, Inc. (referred to herein as “Shuttle Pharmaceuticals,” “Shuttle Pharma” or the “Com

3. Slide 3: The Fundamental Problem of Radiation Therapy

   The Fundamental Problem of Radiation Therapy: Cancers are surrounded by radiation sensitive, dose-limiting normal tissues Sensitization of cancer cells to radiation therapy  Radiation dose determines cancer curability  Radiation therapy limitations are due to sensitive adjacent normal tissues Sens

4. Slide 4: Company Overview: Cancer Treatment Using Radiation Therapy

   Company Overview: Cancer Treatment Using Shuttle Pharma (Nasdaq: SHPH) is a clinical-stage pharmaceutical company, developing next generation drugs and diagnostics to improve outcomes for cancer patients treated with radiation therapy (RT). Therapeutics  Ropidoxuridine is a clinical stage, orally-a

5. Slide 5: Therapeutics – How does Ropidoxuridine (IPdR) work?

   Therapeutics – How does Ropidoxuridine (IPdR) work? Ropidoxuridine (IPdR) is the prodrug of IUdR, a powerful radiation sensitizer, Mechanism reported to improve clinical outcomes of patients treated for brain tumors After oral administration of Ropidoxuridine (IPdR), and sarcomas in NIH supported Ph

6. Slide 6: Ropidoxuridine (IPdR) – Phase II Clinical Trial

   Ropidoxuridine (IPdR) – Phase II Clinical Trial  Phase II study of Ropidoxuridine + RT in IDH wild-type, methylation negative glioblastoma patients.  TCG GreenChem manufactured API, University of Iowa Pharmaceuticals formulated the drug product (capsules).  Theradex Oncology provides CRO services

7. Slide 7: Therapeutics: Selective HDAC Inhibitor Development

   Therapeutics: Selective HDAC Inhibitor Development Therapeutic Pipeline includes histone deacetylase inhibitors for post-RT Mechanism immune stimulation and treatment of ER+ breast cancers. HDAC inhibitors Acetylated Comments and Observations  Novel HDAC inhibitors - discovered and patented by Shut

8. Slide 8: Therapeutics: Clinical and Pre-clinical Development Strategies

   Therapeutics: Clinical and Pre-clinical Development Strategies 1. Clinical development of Ropidoxuridine & RT  Complete the Phase II clinical trial of Ropidoxuridine & RT in glioblastoma brain tumors  Prepare Ropidoxuridine and RT randomized Phase III clinical trial for full marketing approval  S

9. Slide 9: Diagnostics: Clinical Validation of the PC-Rad Test

   Diagnostics: Clinical Validation of the PC-Rad Test PC-Rad Test Kit Components • Calibrants for standard vials/  Market Opportunity: Predictive biomarkers for prostate cancers metabolomics and lipidomics • QC and internal standards  ~ 268,000 new prostate cancer cases annually in the U.S. (inciden

10. Slide 10: Diagnostics: Product Development – PSMA-B ligand

    Diagnostics: Product Development – PSMA-B ligand  The prostate-specific membrane antigen (PSMA) is located on the outside membranes of prostate cancer cells.  The PSMA ligand binds to PSMA, dimerizes, and is internalized into the cell. Radioactive molecules can be attached to the ligand.  Therano

11. Slide 11: Theranostics: PSMA ligand for diagnosis and treatment

    Theranostics: PSMA ligand for diagnosis and treatment Market Opportunity: PSMA imaging and therapy PET Scan Widely metastatic prostate cancer  The Global PSMA PET Imaging Market reached $ 1.5 billion in 2022 and is expected to reach $ 2.0 billion by 2030.  PYLARIFY (piflufolastat F-18) is a radioa

12. Slide 12: Diagnostics: Clinical and Pre-clinical Development Strategies

    Diagnostics: Clinical and Pre-clinical Development Strategies 1. Develop the PC-Rad Test intellectual property as a predictive diagnostics test Predictive Biomarker for Prostate Cancer  Validate the predictive assay in the context of use (COU) for FDA approval.  Perform a muti-institutional clinic

13. Slide 13: Intellectual Property

    Shuttle Pharmaceuticals Holdings, Inc. - Intellectual Property 1. Ropidoxuridine (radiation sensitizers)  Orphan disease designation, manufacturing technology, and method of use patent for the next generation IPdR/TPI formulation. 2. Selective HDAC inhibitors (radiation sensitizers/immune modulator

14. Slide 14: Financial Overview

    Financial Overview Shuttle Pharmaceuticals Capital Market Profile Cap Table Common Stock (as of 12/31/24) 4,076,567 Exchange/Ticker NASDAQ: SHPH March 2025 Offering: Closing Stock Price* $0.265 Common stock issued 1,340,921 Pre-Funded Warrants 17,825,746 52 Wk High/Low* $0.23 - $4.71 Total 19,166,66

15. Slide 15: Experienced Leadership Team

    Experienced Leadership Team Anatoly Dritschilo, MD Christopher Cooper Timothy J. Lorber, CPA Peter Dritschilo, MBA Michael Vander Hoek, MHSA Mira Jung, PhD Tyvin Rich, MD Chairman of the Board of Interim Chief Executive Chief Financial Officer President & COO VP Regulatory Founder & Scientific Direc

16. Slide 16: Thank You

    THANK YOU Shuttle Pharmaceuticals Holdings, Inc. Anatoly Dritschilo, MD Chairman & Chief Scientific Officer Tel: (240) 403-1212 Email: anatoly.dritschilo@ShuttlePharma.org Investor Relations Lytham Partners Robert Blum Tel: (602) 889-9700 Email: SHPH@LythamPartners.com

Shuttle Pharmaceuticals Holdings — Investor Presentation (April 2025) on 6ix